MA43270A - Inhibiteur de la c1 estérase humaine recombinante et ses utilisations - Google Patents

Inhibiteur de la c1 estérase humaine recombinante et ses utilisations

Info

Publication number
MA43270A
MA43270A MA043270A MA43270A MA43270A MA 43270 A MA43270 A MA 43270A MA 043270 A MA043270 A MA 043270A MA 43270 A MA43270 A MA 43270A MA 43270 A MA43270 A MA 43270A
Authority
MA
Morocco
Prior art keywords
inhibitor
recombinant human
human esterase
esterase
recombinant
Prior art date
Application number
MA043270A
Other languages
English (en)
Inventor
Germano Coppola
Angela W Norton
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA43270A publication Critical patent/MA43270A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
MA043270A 2015-11-19 2016-11-18 Inhibiteur de la c1 estérase humaine recombinante et ses utilisations MA43270A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562257711P 2015-11-19 2015-11-19

Publications (1)

Publication Number Publication Date
MA43270A true MA43270A (fr) 2021-06-02

Family

ID=57543175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043270A MA43270A (fr) 2015-11-19 2016-11-18 Inhibiteur de la c1 estérase humaine recombinante et ses utilisations

Country Status (9)

Country Link
US (1) US12209116B2 (fr)
EP (1) EP3377093B1 (fr)
JP (3) JP7189767B2 (fr)
CN (1) CN108463243B (fr)
BR (1) BR112018010160A8 (fr)
CA (1) CA3005906A1 (fr)
ES (1) ES2927271T3 (fr)
MA (1) MA43270A (fr)
WO (1) WO2017087882A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019166572A1 (fr) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase
AU2019325609A1 (en) 2018-08-24 2021-03-18 Csl Behring Gene Therapy, Inc. Vector production in serum free media
JP2022505307A (ja) * 2018-10-17 2022-01-14 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１－ｉｎｈを精製する方法
CN114096558B (zh) * 2019-07-04 2024-10-01 德国杰特贝林生物制品有限公司 纯化c1-inh的方法
SE546553C2 (en) * 2019-10-08 2024-11-26 Hubert Schwarz A method to feed component in perfusion culture
CN115176022A (zh) * 2019-10-23 2022-10-11 夏尔人类遗传性治疗公司 用于遗传性血管性水肿的基于腺相关病毒载体的基因疗法
CN111087475B (zh) * 2019-12-25 2022-07-08 东莞市东阳光生物药研发有限公司 Fgf21融合蛋白及抑制其降解的方法
RU2769201C2 (ru) * 2020-06-23 2022-03-29 Акционерное общество "ГЕНЕРИУМ" Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения
KR20230045615A (ko) * 2020-08-14 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 단백질을 제조하는 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
FR2672895B1 (fr) 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP3543106B2 (ja) * 1999-07-21 2004-07-14 大阪大学長 膜結合型ｃ１インアクチベーター
JP2003521914A (ja) 2000-01-31 2003-07-22 ファーミング インテレクチュアル プロパティー ベー．フェー． トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター
MXPA05000552A (es) 2002-07-15 2005-04-28 Immunex Corp Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
WO2004034971A2 (fr) * 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Procedes de traitement et de prevention de la sepsie au moyen de l'inhibiteur c1 modifie ou de fragments de celui-ci
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7384754B2 (en) 2003-10-31 2008-06-10 Agilent Technologies, Inc. Enrichment and tagging of glycosylated proteins
GB0507123D0 (en) 2005-04-08 2005-05-11 Isis Innovation Method
EP4155385A1 (fr) 2005-12-08 2023-03-29 Amgen Inc. Production amelioree de glycoproteines utilisant le manganese
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
EP1987068B1 (fr) 2006-02-10 2018-08-08 Life Technologies Corporation Modification des oligosaccharides et marquage des protéines
EP2059527B1 (fr) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Glycoprotéines modifiées
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
WO2009049284A2 (fr) 2007-10-12 2009-04-16 Sigma-Aldrich Co. Compositions et procédés pour une sialylation améliorée des glycoprotéines
JP5781308B2 (ja) 2008-02-19 2015-09-16 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 異種タンパク質を得る方法およびインスリン類似体
WO2009143493A2 (fr) * 2008-05-22 2009-11-26 Attagene Inc. Modulateurs des voies de signalisation dépendantes de tnfa et leurs utilisations
EP2166085A1 (fr) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Cellules modifiées bivalentes
CN102317309A (zh) 2009-02-26 2012-01-11 巴特勒能源同盟有限公司 通过不同的翻译后修饰改变和调节蛋白质活性
WO2011116291A1 (fr) * 2010-03-18 2011-09-22 Thrombolytic Science International Production d'un inhibiteur du c1 humain dans des cellules humaines
CA2826337A1 (fr) 2011-02-10 2012-08-16 Manfred Wuhrer Procede de purification d'un glycane et/ou d'un glycoconjugue par chromatographie au moyen d'une phase stationnaire comprenant du coton
WO2013009526A1 (fr) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Procédé de purification d'une protéine de fusion fc
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
ES2587863T3 (es) 2011-12-22 2016-10-27 Csl Behring Gmbh Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central
JP2015512369A (ja) * 2012-03-16 2015-04-27 ベルローズ ファーマ，インコーポレーテッド Ｃ１阻害剤のポリマーコンジュゲート
JP6636334B2 (ja) 2013-03-08 2020-01-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 遠隔虚血再灌流傷害の治療および予防
SMT201900141T1 (it) 2013-03-15 2019-05-10 Shire Viropharma Inc Composizioni di c1-inh e metodi per la prevenzione e il trattamento di disturbi associati a deficit di inibitore di c1 esterasi
CN106255532A (zh) * 2014-02-28 2016-12-21 桑塔鲁斯公司 用c1抑制剂治疗遗传性血管性水肿
MX378753B (es) 2014-03-20 2025-03-10 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albúmina de suero.
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (fr) 2014-11-21 2016-05-26 Kurt Baekgaard Osther Inhibiteur recombinant de la c1-estérase et utilisation de celui-ci
EP3042952A1 (fr) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH Glycoprotéines recombinantes sialylées o-glycanes et lignées cellulaires de production de celles-ci

Also Published As

Publication number Publication date
CA3005906A1 (fr) 2017-05-26
JP7189767B2 (ja) 2022-12-14
EP3377093A1 (fr) 2018-09-26
JP2021155438A (ja) 2021-10-07
ES2927271T3 (es) 2022-11-03
JP7562747B2 (ja) 2024-10-07
BR112018010160A2 (pt) 2018-11-21
CN108463243A (zh) 2018-08-28
BR112018010160A8 (pt) 2019-02-26
CN108463243B (zh) 2022-06-14
US12209116B2 (en) 2025-01-28
US20180334493A1 (en) 2018-11-22
WO2017087882A1 (fr) 2017-05-26
EP3377093B1 (fr) 2022-07-13
JP2023083499A (ja) 2023-06-15
JP2018538270A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
MA43270A (fr) Inhibiteur de la c1 estérase humaine recombinante et ses utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3344624A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP3356416A4 (fr) Anticorps anti-pd-1 et ses utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
KR20180084895A (ko) 효소 내재화 조성물 및 방법
EP3389658A4 (fr) Inhibiteurs de glycosidase et leurs utilisations
MA43552A (fr) Protéines immunomodulatrices à variants de cd80 et leurs utilisations
MA46700A (fr) Variants polypeptidiques et ses utilisations
EP3332008A4 (fr) Modification du gène de la dystrophine et ses utilisations
EP3380100A4 (fr) Inhibiteurs de bromodomaines bivalents et leurs utilisations
EP3341387A4 (fr) Inhibiteurs de sialyltransférase et utilisations de ceux-ci
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3426244A4 (fr) Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations
EP3341007A4 (fr) Inhibiteurs de malt1 et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
MA53991A (fr) Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations
EP3517118A4 (fr) Activateur de sperme et utilisations associées
EP3362754A4 (fr) Inhibiteurs des protéasomes et leurs utilisations
EP3411391A4 (fr) Variants d' ubiquitin et ses utilisations comme inhibiteurs 53bp1
EP3426243A4 (fr) Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations
EP3481860A4 (fr) Hétéromultimères de la superfamille tgf-bêta et leurs utilisations